Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
The SARS-CoV-2 omicron variant has affected which of our COVID-19 treatment strategies are currently effective, with some expected to maintain their efficacy and some expected to lose their efficacy. In this episode, Arthur Kim, MD, discusses the effects of the SARS-CoV-2 omicron variant on many of the COVID-19 approved, authorized, and investigational treatment options, including:
Department of Medicine
Harvard Medical School
Director, Viral Hepatitis Clinic
Division of Infectious Diseases
Massachusetts General Hospital
This program has been made available online.
Prof. Sharon R. Lewin: expert insights on remdesivir for nonhospitalized adult and pediatric patients with COVID-19, from Clinical Care Options (CCO)
Prof. Sharon R. Lewin discusses ivermectin and the evolution of monoclonal antibody treatments during omicron, from Clinical Care Options (CCO)
Megan Coffee, MD, PhD, discusses the newest data on SARS-CoV-2 diagnostics from CROI 2022 and elsewhere, from Clinical Care Options (CCO)
Frequently asked questions and answers: evolving data on COVID-19 epidemiology, prevention, and treatment, from Clinical Care Options (CCO)